Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Prurigo Nodularis: Pilot Study on Efficacy and Safety
TCTR20230227002Phase 3Completed
- Sponsor
- Thammasat University Hospital
- Start
- Jan 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in prurigo nodularis (PN), sponsored by Thammasat University Hospital. Started Jan 2023; status: completed.
02
Drugs
baricitinib
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on TCTR20230227002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230227002.